2. Academic Validation
  3. Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome

Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome

  • J Cannabis Res. 2022 Jan 4;4(1):2. doi: 10.1186/s42238-021-00113-w.
Lyndsey L Anderson 1 2 3,  Michael Udoh 1 2 3,  Declan Everett-Morgan 3,  Marika Heblinski 1 2 3,  Iain S McGregor 1 3 4,  Samuel D Banister 1 3 5,  Jonathon C Arnold 6 7 8
Affiliations

Affiliations

  • 1 Brain and Mind Centre, The University of Sydney, Sydney, NSW, 2050, Australia.
  • 2 Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia.
  • 3 Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, 2050, Australia.
  • 4 School of Psychology, Faculty of Science, The University of Sydney, Sydney, NSW, 2006, Australia.
  • 5 School of Chemistry, Faculty of Science, The University of Sydney, Sydney, NSW, 2006, Australia.
  • 6 Brain and Mind Centre, The University of Sydney, Sydney, NSW, 2050, Australia. jonathon.arnold@sydney.edu.au.
  • 7 Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia. jonathon.arnold@sydney.edu.au.
  • 8 Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, NSW, 2050, Australia. jonathon.arnold@sydney.edu.au.
PMID: 34980287 DOI: 10.1186/s42238-021-00113-w
Abstract

Objective: Cannabigerolic acid (CBGA), a precursor cannabinoid in Cannabis sativa, has recently been found to have anticonvulsant properties in the Scn1a+/- mouse model of Dravet syndrome. Poor brain penetration and chemical instability of CBGA limits its potential as an anticonvulsant therapy. Here, we examined whether CBGA methyl ester, a more stable analogue of CBGA, might have superior pharmacokinetic and anticonvulsant properties. In addition, we examined whether olivetolic acid, the biosynthetic precursor to CBGA with a truncated (des-geranyl) form, might possess minimum structural requirements for anticonvulsant activity. We also examined whether olivetolic acid and CBGA methyl ester retain activity at the epilepsy-relevant drug targets of CBGA: G-protein-coupled receptor 55 (GPR55) and T-type calcium channels.

Methods: The brain and plasma pharmacokinetic profiles of CBGA methyl ester and olivetolic acid were examined following 10 mg/kg intraperitoneal (i.p.) administration in mice (n = 4). The anticonvulsant potential of each was examined in male and female Scn1a+/- mice (n = 17-19) against hyperthermia-induced seizures (10-100 mg/kg, i.p.). CBGA methyl ester and olivetolic acid were also screened in vitro against T-type calcium channels and GPR55 using intracellular calcium and ERK phosphorylation assays, respectively.

Results: CBGA methyl ester exhibited relatively limited brain penetration (13%), although somewhat superior to that of 2% for CBGA. No anticonvulsant effects were observed against thermally induced seizures in Scn1a+/- mice. Olivetolic acid also showed poor brain penetration (1%) but had a modest anticonvulsant effect in Scn1a+/- mice increasing the thermally induced seizure temperature threshold by approximately 0.4°C at a dose of 100 mg/kg. Neither CBGA methyl ester nor olivetolic acid displayed pharmacological activity at GPR55 or T-type calcium channels.

Conclusions: Olivetolic acid displayed modest anticonvulsant activity against hyperthermia-induced seizures in the Scn1a+/- mouse model of Dravet syndrome despite poor brain penetration. The effect was, however, comparable to the known anticonvulsant cannabinoid cannabidiol in this model. Future studies could explore the anticonvulsant mechanism(s) of action of olivetolic acid and examine whether its anticonvulsant effect extends to other seizure types.

Keywords

Anticonvulsant; CBGA; Cannabis; Dravet syndrome; Epilepsy; Olivetolic acid.

Figures
Products